Cotavance^® paclitaxel eluting balloon with Paccocath^® technology to be evaluated in PAD patients combined with plaque excision in DEFINITIVE™ AR study

NOT APPROVED IN THE US.

On August 3, 2011, the next-generation Cotavance catheter was used for the first time in a research setting with the start of patient enrollment in the ev3 DEFINITIVE™ AR (Anti-Restenosis) study in Belgium.

DEFINITIVE AR is a European pilot study sponsored by Covidien and designed to address the challenge of restenosis (narrowing of a blood vessel) in patients with peripheral arterial disease (PAD). The study uses MEDRAD Interventional’s Cotavance^® paclitaxel coated balloon angioplasty catheter with Paccocath^® technology in combination with Covidien’s SilverHawk^® and TurboHawk™ plaque excision systems. 

The Cotavance catheter used in the study is the next generation device currently pending CE Mark.  The advanced version is designed to have:

• A precise paclitaxel coating process for controlled drug dosing;
• A new catheter platform with a full range of catheter sizes; and
• Paccocath technology, a proprietary drug matrix applied to the balloon of the angioplasty catheter consisting of paclitaxel, long used in drug-eluting stents to treat cardiovascular disease, and Ultravist^® 370, a radiologic contrast agent.  When the balloon is inflated to dilate the narrowed vessel, paclitaxel is delivered directly to the diseased area.

“We’re extremely enthusiastic about the opportunity represented by this advanced Cotavance catheter platform,” said Jack Darby, Senior Vice President of MEDRAD Interventional. “Cotavance is the only peripheral paclitaxel eluting balloon catheter using Paccocath technology.  To date, long-term successful treatment of PAD has only been clinically demonstrated with the Paccocath technology.”

DEFINITIVE AR will evaluate whether treating a diseased vessel with plaque excision prior to the use of a drug-eluting balloon (DEB) decreases rates of restenosis compared to DEB treatment alone. DEFINITIVE AR is one of several clinical studies designed to expand treatment options and produce additional long-term data with the Cotavance paclitaxel eluting balloon catheter in the treatment of PAD. Additional planned studies using the next-generation Cotavance catheter include:

• EURO CANAL – a prospective randomized study of patients with infrapopliteal artery stenotic lesions presenting with critical limb ischemia;
• COPA CABANA – a physician-sponsored study of treatment of in-stent restenosis in femoropopliteal arteries; and
• RIVER – a prospective randomized trial for the treatment of superficial femoral or popliteal arteries for FDA approval of Cotavance.

The Cotavance catheter currently pending CE Mark certification is expected to be available in Europe in the second half of 2011. MEDRAD Interventional is also moving forward with the Investigational Device Exemption (IDE) process as one of the steps in gaining FDA approval for Cotavance product in the United States.

________________________________________________
[1] Paccocath, Cotavance, and  Ultravist are trademarks of Bayer and are used under license by MEDRAD, INC. Other trademarks are property of their respective owners.